
Quarterly ResultNov 4, 2026, 08:51 AM
Aprea Therapeutics Q3 Net Loss Widens to $4.81M; Cash Funds Operations into 2028
AI Summary
Aprea Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026. The company reported a net loss of $4.81 million for the third quarter of 2026, an increase from the $2.97 million net loss in the same period of 2025. Operating expenses also rose to $5.17 million from $3.12 million year-over-year. Despite the increased loss, the company's cash position strengthened, with cash and cash equivalents reaching $37.85 million, and management anticipates this will fund operations into the first quarter of 2028.
Key Highlights
- Aprea Therapeutics reported a net loss of $4.81 million for Q3 2026, compared to a net loss of $2.97 million in Q3 2025.
- Total operating expenses increased to $5.17 million in Q3 2026 from $3.12 million in Q3 2025.
- Cash and cash equivalents increased significantly to $37.85 million as of September 30, 2026, from $14.60 million as of December 31, 2025.
- The company's cash balance is expected to fund operations into the first quarter of 2028.
- Net loss per share was $(0.09) for Q3 2026, compared to $(0.47) for Q3 2025.
Price Impact
More from APRE